The facts are:
GLOBALLY, pharma R&D budgets are shrinking and the formula for growth is acquisition. Take a look at these trends over the last couple years and currently. Valeant for example grows almost solely via acquisition with almost no R&D. Major pharma known historically for heavy R&D investments to keep their pipelines full have had numerous failures and when the accumulated costs of those failures reaches up into the TENS of BILLIONS ...... it is cheaper to acquire the candidates and R&D of other companies. PERIOD.
Many drugs are derived from a natural compound. Fact that I have posted here before based on FDA statistics..
$1 per share for a company like ZIVO is petty cash lunch money for any major pharma ..... and even then peaniuts for any pharma/biotech in the top 100. There are multiple potential candidate possible from this biomass.
Dahl needs to get the job of characterization and testing DONE. That makes this company candidate for acquisition if the bioactive performs as described ........ and even more so if the bioactive is novel. Laugh all ya want ...... but if execution gets back on track and the bioactive continues to perform ..... no doubt in my mind big pharma will want to be involved ......
Oh wait ...... big pharma already has interest ...... silly me ....... oh yeah ..... Zoetis hand picked independent CRO that specializes in dairy cows showed the bioactive effective for treatment of mycoplasma bovis ...... presently there is NO TREATMENT for this and this infection typically results in death. Not to mention effective on other common bacteria pathogens that cause masitits. FACT. If effective in cows .... what other animals or even humans might it have an effect on ???
Oh wait ..... bacteria are becoming more and more resistant to antibiotics .... FACT ......
FDA wants to reduce use of antibiotics in animals ..... FACT .....
Oh wait ..... ZIVO has accumulated years of R&D data. Arizona State University, known across the country for its algae expertise, has refined the production process for the biomass and is ready to scale it. FACT.
Other reserach univerities have had success testing the bioactive against other targets. Wayne State, University of Missouri, University of Wisconsin. Even published peer reviewed paper on the results. FACT.
It is really funny the silly ass comments here ....... CAN'T DISPUTE THESE FACTS. And, anyone that does a little work .... and it will take some work ..... CAN VERIFY these on their own.
It is ALL ABOUT MANAGEMENT. MANAGEMENT in a company like this makes all the difference in the world. I'm actually wondering if some of the lack of communication is the result of some acquisition talk or licensing discussion. June shareholder address mentions being in a position to talk licenses. Of course, any discussion of anything with any pharma of size would take months starting with review of data and then the bureaucratic and legal process. No excuse for the outward silence though.
Only time will tell. This stock is a gamble and it may "crap out". We all know it. But the facts are the bioactive is performing. Can management monetize it ????
Amigo Mike
